Clinical trials: Treatment-Resistant Depression
Depression
An Expanded Access Protocol for Esketamine Treatment in Participants With Treatment Resistant Depression (TRD) Who do Not Have Other Treatment Alternatives
The purpose of this expanded access program (EAP) is to provide expanded access to esketamine treatment and collect additional safety data and quality of life until esketamine is commercially available for participants with…
- Trial name
- NCT04476446
- Testing
- Esketamine
- Where
- 8 sites in Mexico
- Volunteers
- 41 people
- Sponsor
- Janssen-Cilag, S.A.
Bipolar Disorder, Depression
A Trial of SAMe for Treatment-Resistant Bipolar Depression
S-adenosyl-L-methionine (SAMe) is a dietary supplement with antidepressant properties. SAMe's mechanism of action remains unclear, but it appears to be distinct from that of conventional antidepressants.
- Conditions
- Bipolar Disorder, Depression, Bipolar Depression
- Trial name
- NCT00762268
- Testing
- SAMe
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Mclean Hospital
Major Depression
Treatment-Resistant Depression, Hippocampus Atrophy and Serotonin Genetic Polymorphism
Reduction of volume of the hippocampus has been associated with major depression in many studies. It has been suggested that antidepressants may protect against hippocampus volume loss in humans associated with multiple episodes…
- Trial name
- NCT00704860
- Testing
- Open label pharmacotherapy
- Where
- Canada
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- University of Ottawa
Treatment Resistant Depression (TRD), Major Depressive Disorder (MDD)
Home-Based Randomized Trial of Spaced Transcranial Direct Current Stimulation for Treatment-Resistant Depression
This study aims to evaluate the clinical efficacy and neurophysiological mechanisms of home-based spaced tDCS in TRD through a randomized, double-blind, sham-controlled trial conducted under remote supervision.
- Trial name
- NCT07834762
- Testing
- Spaced Transcranial Direct Current Stimulation (tDCS)
- Where
- United States
- Volunteers
- 74 people
- Sponsor
- University of California, San Diego
Treatment-Resistant Depression
NRX-101 Expanded Access
The purpose of this Expanded Access Treatment Protocol is to make NRX-101 available to patients who have treatment-resistant depression and who are unable to participate in, or do not have access to, the ongoing NRX-101 clinical…
- Trial name
- NRX-101 EAP (NCT05779267)
- Testing
- NRX-101
- Where
- United States
- Sponsor
- NeuroRx, Inc.
Suicidal Ideation, Major Depressive Disorder
N2O for Acute Suicidality and Depression in the ED
Investigators are conducting this double-blind, randomized control trial (RCT), to compare inhaled N2O+ treatment as usual (TAU) versus inhaled placebo+TAU; demonstrating the feasibility and tolerability of the intervention in an…
- Conditions
- Suicidal Ideation, Major Depressive Disorder, Treatment Resistant Depression
- Trial name
- NCT05710887
- Testing
- Nitrous oxide gas for inhalation
- Where
- United States
- Sponsor
- University of Chicago
Depressive Disorder, Treatment-Resistant
rTMS With and Without Text4Support for the Treatment of Resistant Depression.
This study is a multicenter prospective, parallel design, two-arm, rater-blinded randomized controlled pilot trial. Participants will be randomly assigned to one of two treatment conditions.
- Trial name
- NCT05570344
- Testing
- Repetitive Transcranial Magnetic Stimulation (rTMS), Repetitive Transcranial Magnetic Stimulation (rTMS) Plus Text4Support
- Where
- 2 sites in Canada
- Volunteers
- 200 people
- Sponsor
- University of Alberta
Major Depression
Antidepressant Effects of the Glycine Receptor Antagonist AV-101 (4-chlorokynurenine) in Major Depressive Disorder
Background: Drugs and talk therapy help treat depression, but these treatments usually take quite a bit of time to work. Ketamine is a fast-acting antidepressant, but it has side effects like unusual dreams and experiences.
- Trial name
- NCT02484456
- Testing
- AV 101 (4-Chlorokynurenine)
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- National Institute of Mental Health (NIMH)
Depression
Magnesium Sulfate Versus 5% Dextrose With Treatment Resistant Depression
The proposed study is a 1-week, randomized, double-blind, placebo-controlled, trial to evaluate the efficacy of an IV infusion of magnesium sulfate on symptoms of treatment resistant mild and moderate depression in 20 males and…
- Trial name
- NCT01597167
- Testing
- Magnesium sulfate
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- University of Miami
Major Depression, Generalized Anxiety Disorder
Study of the Changes in Metabolic Parameters in Patients Treated With Escitalopram for Six Months
The purpose of this study is to explore the changes in metabolic parameters in patients treated with escitalopram for six months for major depression, generalized anxiety disorder or panic disorder, with or without agoraphobia.
- Conditions
- Major Depression, Generalized Anxiety Disorder, Panic Disorder
- Trial name
- NCT00711737
- Where
- Singapore
- Volunteers
- 27 people
- Sponsor
- Changi General Hospital
Psychiatric Disorder, Major Depressive Disorder
Exploring Blood Plasma Metabolomics: Unraveling the Metabolic Landscape in Treatment-Resistant Adolescent Depression
This study contributes new evidence for the identification of adolescent TRD and sheds light on differing pathophysiologies by delineating distinct plasma metabolic profiles between adolescent TRD and FEDN-MDD.
- Conditions
- Psychiatric Disorder, Major Depressive Disorder, Metabolic Disorder
- Trial name
- NCT06331572
- Testing
- 17-HAMD
- Where
- China
- Volunteers
- 162 people, healthy volunteers welcome
- Sponsor
- First Affiliated Hospital of Chongqing Medical University
Treatment Resistant Depression
Vagus Nerve Stimulation (VNS) Electroencephalogram (EEG) Protocol Supplement
The study will examine the autonomic, physiologic and neurophysiologic effects of implanted Vagus Nerve Stimulation (VNS) in treatment-resistant depression patients.
- Trial name
- NCT07310381
- Testing
- Vagus Nerve Stimulation
- Volunteers
- 12 people
- Sponsor
- Stanford University
Treatment Resistant Depression
The Safety and Efficacy Of Psilocybin as an Adjunctive Therapy in Participants With Treatment Resistant Depression
The Safety and Efficacy of Psilocybin as an Adjunctive Therapy in Participants with Treatment-Resistant Depression
- Trial name
- NCT04739865
- Testing
- Psilocybin
- Where
- 2 sites in United States, Ireland
- Volunteers
- 19 people
- Sponsor
- COMPASS Pathways
Bipolar Depression, Treatment Resistant Depression
Intensive TMS for Bipolar Depression
The research study is being conducted to test whether using high dose spaced theta-burst rTMS (a form of transcranial magnetic stimulation) produces a significant reduction in depressive symptoms compared with sham.
- Trial name
- NCT05228457
- Testing
- Intensive intermittent theta-burst stimulation (iTBS)
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- University of Pennsylvania
Patients With Resistant Depressive Disorders
Monocentric Pilot Study, for a Randomized, Crossover, Blinded Trial: Comparison of the Therapeutic Efficacy of Low Frequency Repeated Transcranial Magnetic Stimulation on Cortical Area 9 Compared to Brodmann Area 46 in the Treatment of Depressive Disorders.
Repetitive transcranial magnetic stimulation (rTMS) is a new therapeutic tool used in psychiatry. Non-invasive, well tolerated and requiring no premedication, it is performed on an outpatient basis.
- Trial name
- rTMS (NCT03656900)
- Testing
- rTMS BA9/BA46, rTMS BA46/BA9, brain MRI
- Where
- France
- Volunteers
- 17 people
- Sponsor
- Centre Hospitalier Universitaire Dijon
Major Depressive Disorder
Treatment Resistant Geriatric Depression in Primary Care
This study involves collaboration between McLean Hospital, Geriatric Medicine at the Cambridge Health Alliance (CHA) and other sites within the Partners and Harvard Medical School network.
- Trial name
- NCT01392287
- Testing
- Memantine
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Mclean Hospital
Bipolar Depression Depressed Phase
Low Frequency Right Dorsolateral Pre Frontal Cortical Repetitive TMS for Bipolar Depression
The purpose of this trial is to conduct an adequately powered clinical trial of once daily LFR for individuals diagnosed with treatment-resistant BD-DE who have not responded to iTBS or sham treatment applied to the left DLPFC.
- Trial name
- FLARE (NCT06986460)
- Testing
- MagPro X100/R30 stimulator, Cool-B70 coil
- Where
- 2 sites in Canada
- Volunteers
- 80 people
- Sponsor
- Tyler Kaster
Treatment Resistant Depression, Major Depressive Disorder
Mechanistic Evaluation of Response in TRD (MERIT)
To evaluate the relapse prevention of AXS-05 relative to placebo in subjects with treatment resistant depression (TRD). This is a randomized, double-blind, placebo-controlled study to evaluate AXS-05 compared to placebo in…
- Trial name
- MERIT (NCT04608396)
- Testing
- AXS-05
- Where
- 20 sites in United States
- Volunteers
- 44 people
- Sponsor
- Axsome Therapeutics, Inc.
Major Depressive Disorder (MDD)
The Effect of Transcranial Magnetic Stimulation Treatment on Microvasculature Stracture of the Retina and the Choroid
Transcranial Magnetic Stimulation (TMS) therapy is an approved and effective treatment option in treatment-resistant depression.
- Trial name
- TMS_OCT-A (NCT06708013)
- Testing
- Transcranial Magnetic Stimulation
- Where
- Turkey (Türkiye)
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Gulhane Training and Research Hospital
Depressive Episode, Electroconvulsive Therapy
Electroconvulsive Treatment Followed by Cognitive Control Training
Major depressive disorder (MDD) is worldwide one of the most prevalent and disabling mental health conditions. Electroconvulsive therapy (ECT) is a safe and effective treatment even though 6-month relapse rates are high.
- Conditions
- Depressive Episode, Electroconvulsive Therapy, Cognitive Remediation
- Trial name
- ECT-CCT (NCT04383509)
- Testing
- Cognitive Control Training, Active Control
- Where
- Belgium
- Volunteers
- 21 people
- Sponsor
- University Ghent